NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

NexImmune, a US-based cancer immunotherapy spinout of Johns Hopkins University, raised $110m in an upsized initial public offering on the Nasdaq Global Market on Thursday, providing exits to pharmaceutical firms Amgen and Pfizer.
The company issued nearly 6.5 million shares priced at $17, the top of its range, and shares closed at $25.33 on the first day of trading on Friday. It had originally aimed for $86.3m in proceeds when it first filed last month.
Founded…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in